Pharmacoeconomic considerations in the treatment of breast cancer

ClinicoEconomics and Outcomes Research

Volumn 2, Issue 1, 2010, Pages 47-61

  Pallis, Athanasios ^a   Tsiantou, Vasiliki ^b   Simou, Efi ^b   Maniadakis, Nikos ^b  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

Author keywords

Breast cancer; Cost; Pharmacoeconomics

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; GEMCITABINE; GONADORELIN; IBANDRONIC ACID; LAPATINIB; LETROZOLE; MEGESTROL ACETATE; METHOTREXATE; MITOMYCIN C; NAVELBINE; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ADVANCED CANCER; ARTHRALGIA; BONE DENSITY; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; DRUG MECHANISM; FRACTURE; HEALTH CARE COST; HEALTH ECONOMICS; HOT FLUSH; HUMAN; LYMPH NODE DISSECTION; MASTECTOMY; MULTIPLE CYCLE TREATMENT; POSTMENOPAUSE; PREMENOPAUSE; REVIEW; RISK FACTOR; SIDE EFFECT;

EID: 77955458438     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581-592.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
3. Berrino F, De AR, Sant M, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: Results of the EUROCARE-4 study. Lancet Oncol. 2007;8(9): 773-783.
4. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
5. Wood RB, Muss H, Solin LJ, Olopade OI. Malignant tumors of the breast. In: DeVita VT, Hellman S, Rosenberg SA, editors. Principles and Practice of Oncology. 7th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2005. p.1415-1477.
6. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
7. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2001;2(3):133-140.
8. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002;76(1):27-36.
9. Campbell J, Scott R. The costs of treating breast cancer in the US: A synthesis of published evidence. Pharmacoeconomics. 2009;27(3):199-209.
10. Barron J. Quimbo R, Nikam P, Amonkar M. Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat. 2008;109(2):367-377.
11. Max W, Sung HY, Stark B. The economic burden of breast cancer in California. Breast Cancer Res Treat. 2009;116(1):201-207.
12. Lidgren M, Wilking N, Jonsson B, Rehnberg C. Resouce use and costs associated with different states of breast cancer. Int J Technol Assess Health Care. 2007;23(2):223-231.
13. Lidgren M, Wilking N, Jonnson B. Cost of breast cancer in Sweden in 2002. Eur J Health Econ. 2007;8(1):5-15.
14. Pelletier EM, Shim B, Goodman S, Amonkar MM. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: Results from a US claims data analysis. Breast Cancer Res Treat. 2008;108(2):297-305.
15. Delea T, MacKeirnan J, Brandman J, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol. 2006;4(7):341-347.
16. Rao S, Kubisiak J, Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat. 2004;83(1):25-32.
17. Hensley ML, Dowell J, Herndon JE 2nd, et al. Economic outcomes of breast cancer survivorship: CALGB study 79804. Breast Cancer Res Treat. 2005;91(2):153-161.
18. Lamerato L, Havstad S, Gandhi S, Jones D, Nathanson D. Economic burden associated with breast cancer reoccurrence: Findings from a retrospective analysis on health system data. Cancer. 2006;106(9): 1875-1882.
19. Simmons RM, Adamovich TL. Skin-sparing mastectomy. Surg Clin North Am. 2003;83(4):885-899.
20. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995;333(22):1456-1461.
21. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233-1241.
22. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227-1232.
23. van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Nat Cancer Inst. 2000;92(14):1143-1150.
24. Jacobson JA, Danforth DN, Cowan KH, et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med. 1995;332(14):907-911.
25. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30): 7703-7720.
26. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20(8):1319-1329.
27. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348(24):2431-2442.
28. Parton M, Smith IE. Controversies in the management of patients with breast cancer: Adjuvant endocrine therapy in premenopausal women. J Clin Oncol. 2008;26(5):745-752.
29. Lin NU, Winer EP. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol. 2008;26(5):798-805.
30. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treat-ment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet. 2002;359(9324):2131-2139.
31. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365(9453): 60-62.
32. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747-2757.
33. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081-1092.
34. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet. 2007;369(9561):559-570.
35. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366(9484):455-462.
36. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 2005;23(22):5138-5147.
37. Boccardo F, Rubagotti A, Guglielmini P, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol. 2006; Suppl 7:vii10-vii14.
38. Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: Results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007;99(24):1845-1853.
39. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793-1802.
40. Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol. 2008;26(12): 1965-1971.
41. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679-691.
42. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000;18(22):3748-3757.
43. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001;19(10):2596-2606.
44. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000;18(22): 3758-3767.
45. Vergote I, Bonneterre J, Thurlimann B, et al. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. Eur J Cancer. 2000;36 Suppl 4:S84-S85.
46. Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008;26(30):4883-4890.
47. Jonat W, Gnant M, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: A meta-analysis. Lancet Oncol. 2006;7(12):991-996.
48. NCCN Clinical Practice Guidelines in Oncology. Volume 1. 2009. Breast Cancer. Available from: http://www.nccn.org/professionals/phy-sician_gls/f_guidelines.asp. Accessed Mar 9, 2010.
49. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360(8):790-800.
50. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clin Oncol. 2008;26(1):44-53.
51. Cardoso F, Bedard PL, Winer EP, et al. International guidelines for management of metastatic breast cancer: Combination vs sequential single-agent chemotherapy. J Natl Cancer Inst. 2009;101(17): 1174-1181.
52. Carrick S, Parker S, Wilcken N, Ghersi D, Marzo M, Simes J. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2005;(2):CD003372.
53. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). J Clin Oncol. 2003;21(4):588-592.
54. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol. 2002;20(12):2812-2823.
55. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-2676.
56. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287-5312.
57. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER-2. N Engl J Med. 2001;344(11):783-792.
58. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008;26(10):1642-1649.
59. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006;24(18):2786-2792.
60. Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. Cancer. 2007;110(5):965-972.
61. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2- overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719-726.
62. Bartsch R, Wenzel C, Altorjai G, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol. 2007;25(25):3853-3858.
63. von MG, du BA, Schmidt M, Maass N, Cufer T, de Jongh FE, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: German breast group 26/breast international group 03-05 study. J Clin Oncol. 2009;27(12):1999-2006.
64. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER-2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-2743.
65. O'Shaughnessy J, Blackwell KL, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER-2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol. 2009;26(20 Suppl):Abstr 1015.
66. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684.
67. Piccart-Gebhart MJ, Procter M, et al. Trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer. N Engl J Med. 2005;353(16):1659-1672.
68. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809-820.
69. Robert NJ, Eirmann W, Pienkowski T, et al. BCIRG 006: Docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: Quality of life (QOL) at 36 months follow-up. J Clin Oncol. 2007;25(18S):Abstr 19647.
70. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042-4057.
71. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol. 1999;17(3):846-854.
72. Rosen LS, Gordon DH, Dugan W Jr, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100(1):36-43.
73. Diel IJ, Body JJ, Lichinitser MR, et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer. 2004;40(11):1704-1712.
74. Folkestad L, Bjarnason NH, Bjerregaard JK, Brixen K. The effect of aromatase inhibitors on bone metabolism. Basic Clin Pharmacol Toxicol. 2009;104(1):3-10.
75. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA17. J Natl Cancer Inst. 2005;97(17):1262-1271.
76. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26(8): 1231-1238.
77. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23(31):7811-7819.
78. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol. 2007;25(23):3525-3533.
79. Lin NU, Winer EP. Brain metastases: The HER-2 paradigm. Clin Cancer Res. 2007;13(6):1648-1655.
80. Eckermann SD, Martin AJ, Stockler MR, Simes RJ. The benefits and costs of tamoxifen for breast cancer prevention. Aust N Z J Public Health. 2003;27(1):34-40.
81. Karnon J, Brown J on behalf of the ABC Steering Committee. Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: A stochastic evaluation. Pharmacoeconomics. 2002;20(2): 119-137.
82. Thompson D, Taylor DC, Montoya EL, Winer EP, Jones SE, Weinstein MC. Cost effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early stage breast cancer. Value in Health. 2007;10(5):367-376.
83. Risebrough NA, Verma S, Trudeau M, Mittmann N. Cost effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for post menopausal women with primary breast cancer. Cancer. 2007;110(3):499-508.
84. Lundkvist J, Wilking N, Holmberg S, Jonnson L. Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. Breast Cancer Res Treat. 2007;102(3):289-299.
85. Hillner BE, Radice D. Cost effectiveness of exemestane compared with megestrol in patients with advanced breast carcinoma. Cancer. 2001;91(3):484-489.
86. Lindgren P, Jonsson B. Radaelli A, Radice D. Cost effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: A model for Europe and Australia. Pharmacoeconomics. 2002;20(2):101-108.
87. Nuijten M, Meester L, Waibel F, Wait S. Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK. Pharmacoeconomics. 1999;16(4):379-397.
88. Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A. Taxanes for the adjuvant treatment of early breast cancer: Systematic review and economic evaluation. Health Technol Assess. 2007;11(40):1-144.
89. Limwattananon S, Limwattananon C, Maoleekulpairoj S, Soparatanapaisal N. Cost effectiveness analysis of sequential paclitaxel adjuvant chemotherapy for patients with node positive primary breast cancer. J Medical Assoc Thai. 2006;89(5):690-698.
90. Brown RE, Hutton J, Burrell A. Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics. 2001;19(11):1091-1102.
91. Leung PP, Tannock IF, Oza AM, Puodziunas A, Dranitsaris G. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel or vinorelbine for patients with anthracycline-resistant breast cancer. J Clin Oncol. 1999;17(10):3082-3090.
92. Vu T, Ellard S, Speers CH, et al. Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: A population based evaluation. Ann Oncol. 2008;19(3): 461-464.
93. Li N, van Agthoven M, Willemse PH, Uyl-de Groot CA. A cost-utility analysis comparing second line chemotherapy schemes in patients with metastatic breast cancer. Anti-Cancer Drugs. 2001;12(6):533-540.
94. Verma S, Illersich AL. Population based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer. Oncologist. 2003;8(3):232-240.
95. Ravasio R, Giuliani G, Veronesi A. Cost-efficacy of capecitabine and docetaxel in combination compared with docetaxel monotherapy in patients with metastatic breast cancer pre-treated with anthracyclines. Pharmacoeconomics. 2005;7(1):59-66.
96. Verma S, Maraninchi D, O'Shaughnessy J, et al. Capecitabine plus docetaxel combination therapy. Cancer. 2005;103(12):2455-2465.
97. Takeda AL, Jones J, Loveman E, Tan SC, Clegg AJ. The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: A systematic review and economic evaluation. Health Technol Assess. 2007;11(19):iii, ix-xi, 1-62.
98. National Institute for Health and Clinical Excellence. Advanced breast cancer: Diagnosis and treatment. NICE technology appraisal guidance. Number 62, 2009. Available from: www.nice.org.uk/pdf/BreastcancerlapatinibFAD.pdf. Accessed March 07, 2010.
99. Chan AL, Leung HW, Lu CL, Lin SJ. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: A systematic review. Ann Pharmacother. 2009;43(2):296-303.
100. National Institute for Health and Clinical Excellence. Trastuzumab for the adjuvant treatment of early stage HER2-positive breast cancer. NICE technology appraisal guidance. 2006. Available from: www.nice.org.uk/nicemedia/pdf/TA107guidance.pdf. Accessed March 9, 2010.
101. Van V I, Canon JL, Cocquyt V, et al. Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities. Acta Clin Belg. 2009;64(2):100-112.
102. Neyt M, Huybrechts M, Hulstaert F, Vrijens F, Ramaekers D. Trastuzumab in early stage breast cancer: A cost effectiveness analysis for Belgium. Health Policy. 2008;87:146-159.
103. Millar JA, Millward MJ, Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: A lifetime model. Pharmacoeconomics. 2007;25(5):429-442.
104. Botteman M, Barghout V, Stephens J, Hay J, Brandman J, Aapro M. Cost effectiveness of bisphsphonates in the management of breast cancer patients with bone metastases. Ann Oncol.2006;17(7): 1072-1082.
105. Guest JF, Clegg JP, Davie AM, McCloskey E. Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK. Curr Med Res Opin. 2005;21(5): 805-815.
106. Slof J, Badia X, Lizan L, et al. Zoledronic acid versus pamidronate: Cost-minimization in bone metastasis. J Med Econ. 2005;8:1-12.
107. De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee MP, Lewis G. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. Clin Ther. 2005;27(8):1295-1310.
108. Reed SD, Radeva JI, Glendenning GA, Coleman RE, Schulman KA. Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. Am J Clin Oncol. 2005;28(1):8-16.
109. Hillner BE, Weeks JC, Desch CE, Smith TJ. Pamidronate in prevention of bone complications in metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol. 2000;18(1):72-79.
110. Dranitsaris G. Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer. 1999;7(4):271-279.
111. Body JJ. Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer. 2003;97(3 Suppl):859-865.
112. Burdette-Radoux S, Muss HB. A question of duration: Do patients with early-stage breast cancer need more than five years of adjuvant endocrine therapy? Clin Breast Cancer. 2009;9 Suppl 1:S37-S41.
113. Delea TE, El-Ouagari K, Karnon J, Sofrygin O. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat. 2008;108(3):375-387.
114. Ouagari KE, Karnon J, Delea T, Talbot W, Brandman J. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res Treat. 2007;101(1):37-49.
115. Karnon J, Johnston SR, Jones T, Glendenning A. A trial based cost effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer. Ann Oncol. 2003;14(11):1629-1633.
116. Rocchi A, Verma S. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. Support Care Cancer. 2006;14(9): 917-927.
117. Locker GY, Mansel R, Cella D, Dobrez D, Sorensen S, Gandhi SK; ATAC Trialists Group. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: A US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat. 2007;106(2):229-238.
118. Mansel R, Locker G, Fallowfield L, Benedict A, Jones D. Cost-effectiveness analysis of anastrozole vs. tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial. Br J Cancer. 2007;97(2):152-161.
119. Moeremans K, Annemans L. Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer: Analysis based on the ATAC trial. Int J Gynecol Cancer. 2006;16(Suppl 2): 576-578.
120. Piskur P, Sonc M, Cufer T, Borstnar S, Mrhar A. Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: A Slovenian perspective. Anti-Cancer Drugs. 2006;17(6): 719-724.
121. Ouagari KE, Karnon J, Delea T, Talbot W, Brandman J. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res Treat. 2007;101(1):37-49.
122. Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, Goss PE. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early stage breast cancer. Am J Manag Care. 2006;12(7):374-386.
123. Hind D, Ward S, De NE, Simpson E, Carroll C, Wyld L. Hormonal therapies for early breast cancer: Systematic review and economic evaluation. Health Technol Assess. 2007 July;11(26):iii-xi, 1.
124. Cuzick J, Ambroisine L, Davidson N, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007 May 19;369(9574):1711-1723.
125. Gibson LJ, Dawson CK, Lawrence DH, Bliss JM. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2007;(1):CD003370.
126. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol. 2001;19(14):3357-3366.
127. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer. 1998;83(6):1142-1152.
128. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998;16(2):453-461.
129. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol. 2000;18(7):1399-1411.
130. Karnon J, Jones T. A stochastic economic evaluation of letrozoleversus tamoxifen as a first-line hormonal therapy: For advanced breast cancer in postmenopausal patients. Pharmacoeconomics. 2003;21(7): 513-525.
131. Advanced breast cancer: Diagnosis and treatment. Full Guideline developed for NICE by the National Collaborating Centre for Cancer. February 2009. Available from: http://www.nice.org.uk/nicemedia/pdf/CG81FullGuideline.pdf. Accessed March 9, 2010.
132. Torrisi R, Bagnardi V, Pruneri G, et al. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer. 2007;97(6):802-808.
133. Forward DP, Cheung KL, Jackson L, Robertson JF. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer. 2004;90(3):590-594.
134. Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2007;25(6):625-633.
135. Norum J, Olsen JA, Wist EA, Lonning PE. Trastuzumab in adjuvant breast cancer therapy: A model based cost-effectiveness analysis. Acta Oncol. 2007;46(2):153-164.